Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.
Autoimmune encephalitis
CASPR2
LGI1
NMDAR
Neurofilament light chain
NfL
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
27
02
2019
accepted:
01
04
2019
revised:
28
03
2019
pubmed:
5
4
2019
medline:
31
12
2019
entrez:
5
4
2019
Statut:
ppublish
Résumé
Circulating and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels represent a reliable indicator of disease activity and axonal damage in different neuroinflammatory conditions. Recently, high CSF NfL levels have been detected in active autoimmune encephalitis, as opposed to significant lower levels after clinical improvement. The aim of the present study was to evaluate serum and CSF NfL concentration in patients with autoimmune encephalitis and to analyse the association between NfL levels and clinical, MRI, and CSF data. We retrospectively included 25 patients with neurological syndromes associated with autoantibodies to neuronal cell surface antigens and we collected clinical, MRI, CSF, and follow-up data. Using an ultrasensitive method (Simoa, Quanterix), we measured NfL levels in serum and CSF samples of all patients and in 25 sera of healthy controls. Serum NfL levels were higher in all cases, including 20 patients with inflammatory MRI/CSF features and 5 non-inflammatory cases (median 16.9 pg/ml, range 4.5-90) than in controls (median 6.9 pg/ml, range 2.7-12.8; p < 0.001). A correlation between serum and CSF NfL levels was found (r = 0.461, p = 0.023), whereas no significant association was observed between NfL levels and clinical, MRI/CSF inflammatory burden, and antibody type. In the 13 available follow-up samples, correlation between disease activity and NfL values was also observed. In conclusion, NfL levels are significantly increased in the serum of patients with antibody-mediated encephalitis, independently of the MRI/CSF inflammatory profile. These findings support the presence of ongoing axonal damage and suggest the co-occurrence of different mechanisms for neuronal/axonal involvement in antibody-associated CNS syndromes.
Identifiants
pubmed: 30944980
doi: 10.1007/s00415-019-09306-z
pii: 10.1007/s00415-019-09306-z
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1643-1648Subventions
Organisme : Ministero della Salute
ID : RF-2011-0234-7955
Références
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Acta Neuropathol. 2009 Dec;118(6):737-43
pubmed: 19680671
Brain. 2010 Jun;133(Pt 6):1655-67
pubmed: 20511282
Brain. 2012 May;135(Pt 5):1622-38
pubmed: 22539258
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Ann Neurol. 2013 Aug;74(2):284-96
pubmed: 23686722
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
Front Immunol. 2015 Apr 29;6:206
pubmed: 25972873
Mult Scler. 2016 Oct;22(12):1550-1559
pubmed: 26754800
Eur J Neurol. 2016 Apr;23(4):796-806
pubmed: 26822123
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
Eur J Neurol. 2017 May;24(5):703-712
pubmed: 28261960
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
J Neuroimmunol. 2017 May 15;306:25-30
pubmed: 28385184
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Lancet Neurol. 2017 Aug;16(8):601-609
pubmed: 28601473
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
Mult Scler J Exp Transl Clin. 2017 Nov 22;3(4):2055217317743098
pubmed: 29204292
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
J Neurol. 2018 Mar;265(3):510-521
pubmed: 29322259
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Neurology. 2018 Apr 3;90(14):e1231-e1239
pubmed: 29514947
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Neuropathol Appl Neurobiol. 2019 Apr;45(3):291-304
pubmed: 29908069
Parkinsonism Relat Disord. 2018 Nov;56:98-101
pubmed: 29937097